Associated Genetic Biomarkers
BCL2L11 is altered in 0.44% of all cancers with non-small cell lung carcinoma, uterine corpus neoplasm, colorectal adenocarcinoma, prostate cancer, and breast carcinoma having the greatest prevalence of alterations .
The most common alterations in BCL2L11 are BCL2L11 Loss (0.03%), BCL2L11 R153W (0.01%), BCL2L11 E176K (0.01%), BCL2L11 Y162* (0.01%), and BCL2L11 A32T (0.00%) .
BCL2L11 status serves as an inclusion eligibility criteria in 4 clinical trials, of which 4 are open and 0 are closed. Of the trials that contain BCL2L11 status as an inclusion criterion, 4 are phase 2 (4 open).
Trials with BCL2L11 status in the inclusion eligibility criteria most commonly target non-small cell lung carcinoma .
The most frequent alteration to serve as an inclusion eligibility criterion is BCL2L11 Deletion .
Carboplatin, gefitinib, avitinib maleate, tucidinostat, and x-396 are the most frequent therapies in trials with BCL2L11 as an inclusion criteria .
Significance of BCL2L11 in Diseases
Non-Small Cell Lung Carcinoma +
BCL2L11 is mutated in 0.37% of non-small cell lung carcinoma patients .
BCL2L11 is an inclusion criterion in 4 clinical trials for non-small cell lung carcinoma, of which 4 are open and 0 are closed. Of the trials that contain BCL2L11 status and non-small cell lung carcinoma as inclusion criteria, 4 are phase 2 (4 open) .
Carboplatin, gefitinib, and avitinib maleate are the most frequent therapies in non-small cell lung carcinoma trials with BCL2L11 alterations as inclusion criteria .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.